文献速递消化系统肿瘤

Aflibercept联合5-FU对比FOLFOX一线治疗老年或体弱转移性结直肠癌的随机II期试验

Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629).
PubMed 文献 · Eur J Cancer · 2026-03-24

该非比较性随机II期研究纳入120例≥70岁或体弱的初治转移性结直肠癌患者,随机接受减量mFOLFOX7(A组)或阿柏西普联合减量5-FU(B组)。A组6个月无进展生存率为68%,B组为46%;A组中位无进展生存期7.9个月,B组5.5个月。两种方案在老年体弱人群中可行,A组疗效和3个月整体治疗效用更优。

要点

  • 减量mFOLFOX7的6个月PFS率68%,优于阿柏西普联合5-FU的46%。
  • A组中位PFS 7.9个月,B组5.5个月;中位OS分别为20.4和19.0个月。
  • B组≥3级治疗相关严重不良事件发生率17%,高于A组的5%。

核心结论

  • 减量mFOLFOX7和阿柏西普联合减量5-FU在老年或体弱mCRC患者中均可行。
  • 减量mFOLFOX7显示出较好的PFS和3个月整体治疗效用,阿柏西普联合5-FU次之。
  • 尽管多数患者体弱,生存率仍较有希望,可能归因于有效的后续治疗。

研究设计与样本

  • 开放标签、多中心、随机II期非比较性研究,纳入初治转移性结直肠癌患者。
  • 患者≥70岁或体弱,1:1随机至减量mFOLFOX7组(A组)或阿柏西普(4 mg/kg)联合减量mLF5FU2组(B组)。
  • 全分析人群120例(A组62例,B组58例),男性63%,中位年龄78.5岁,体弱患者占82%。

主要发现

  • 6个月PFS率:A组68%[95%CI 56%;80%],B组46%[32%;59%]。
  • 中位PFS:A组7.9个月,B组5.5个月;中位OS:A组20.4个月,B组19.0个月。
  • ORR:A组47%,B组22%。
  • 3个月整体治疗效用良好者比例:A组52%,B组35%。
  • B组最常见≥3级不良事件为高血压(41%)和蛋白尿(10%);≥3级治疗相关严重不良事件B组17%,A组5%。

临床怎么用

  • 对于不适合全剂量联合化疗的老年或体弱mCRC患者,减量mFOLFOX7可作为一线治疗选择。
  • 阿柏西普联合减量5-FU也可行,但需注意高血压和蛋白尿等不良事件。

局限性

  • 本研究为非比较性II期试验,样本量有限。
  • 多数患者体弱,生存率可能受后续治疗影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fluoropyrimidines + angiogenesis inhibitor or dose-reduced doublets are used for (frail) elderly patients with metastatic colorectal cancer (mCRC). This non-comparative trial evaluated two 1st line regimens for patients not eligible for full-dose combinations. METHODS: This open-label, multicenter, phase II study randomized untreated mCRC patients ≥ 70 years ± frailty 1:1 to dose reduced mFOLFOX7 in Arm A or aflibercept (4 mg/kg) plus dose reduced mLV5FU2 in Arm B. Primary endpoint was the 6-months PFS rate (PFS@6), secondary endpoints included safety, overall survival (OS), overall response rate (ORR), patient reported outcomes and overall treatment utility (OTU). FINDINGS: The full analysis population comprised 120 patients (62 Arm A, 58 Arm B; 63% male), with a median age of 78.5 years. 82% frail patients were included. PFS@6 was 68% [95%CI 56%;80%] in Arm A and 46% [32%;59%] in Arm B. Median PFS was 7.9 and 5.5 months, median OS was 20.4 and 19.0 months and ORR was 47% and 22% in Arm A and B, respectively. At 3 months, 52% in Arm A and 35% in Arm B had a good OTU. Most frequent grade ≥ 3 AEs in Arm B were hypertension (41%) and proteinuria (10%). More patients in arm B had treatment-related SAEs grade ≥ 3 (17% in arm B and 5% in arm A). INTERPRETATION: Both regimens were feasible in this (frail) elderly population. Dose-reduced mFOLFOX7 and, to a lesser extent, 5-FU/aflibercept showed good PFS and 3-month OTU. Although most patients were regarded frail, survival rates were promising, most likely due to effective further-line treatments.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hofheinz RD, Weikersthal LFV, Dechow T, et al. Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629). Eur J Cancer. 2026. PMID: 41905242. doi:10.1016/j.ejca.2026.116689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。